speeding the development of new therapies and diagnostics ...10:21 – 10:51 am • graybug vision,...

Follow the meeting on Twitter: #Glaucoma360

Speeding the development of new therapies and diagnostics for glaucoma patients

New Horizons ForumFriday, February 9, 2018

Palace Hotel, San Francisco, CA

© Aerie Pharmaceuticals, Inc. Irvine, CA 92614MLR-0002

12018 New Horizons Forum

It is our sincere pleasure to welcome you to the 7th Annual Glaucoma 360: New Horizons Forum, hosted by Glaucoma Research Foundation. This important meeting provides a unique opportunity to bring together leaders in medicine, science, industry, venture capital, and the FDA to discuss emerging ideas in glaucoma and encourage collaboration to accelerate their development for clinical use.

Since its establishment in 2012, this annual forum continues to grow and provide the ultimate opportunity to highlight important advances and facilitate networking between these essential groups. As a result, there are now more effective therapies and diagnostic tools in clinical practice today to help doctors manage the disease more effectively.

But, unmet medical needs remain in glaucoma. Glaucoma Research Foundation is resolute in its mission to preserve vision and continue its role as a catalyst in the advancement of research towards new treatments and a cure.

Glaucoma 360 would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board, Program and Steering Committees who have volunteered their time to build an outstanding agenda; our dedicated sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspectives; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at The Palace Hotel. Over the past seven years, the field has grown substantially and we are honored and grateful to all of you, for your ongoing dedication to helping patients. Because of your commitment, we now have more options to care for patients than ever before.

All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors such as the Catalyst for a Cure, a unique collaborative approach to uncover new diagnostic and treatment options for glaucoma. Thank you for your wonderful partnership in our mission. Together, we can truly make a difference in the lives of people living with glaucoma.

Adrienne L. Graves, PhD Andrew G. Iwach, MDCo-Founder and Co-Chair, Glaucoma 360 Co-Founder and Co-Chair, Glaucoma 360Director, Glaucoma Research Foundation Board Chair, Glaucoma Research Foundation

WELCOMEGlaucoma Research Foundation thanks the following sponsors for their generous support of Glaucoma 360

PLATINUM

SILVER

BRONZE

Akorn, Inc.Beaver-Visitec International

EllexHaag-Streit USAIcare USA, Inc.

Optos, Inc.Optovue, Inc.

Quantel MedicalShire

Sight Sciences, Inc.

IRIDEX CorporationLumenis Vision

Mobius Therapeutics, LLCNidek Inc.

Ophthalmic Mutual Insurance Company

Wi-Fi sponsored by Santen Inc., Network: Palace Meetings, Password: 2018G360

2 Glaucoma Research Foundation 32018 New Horizons Forum

PROGRAM Follow the meeting on Twitter: #Glaucoma360

7:30 – 8:00 am REGISTRATION, BREAKFAST AND EXHIBITS

8:00 – 8:06 am WELCOME AND OPENING REMARKS Adrienne L. Graves, PhD and Andrew G. Iwach, MD Co-Founders and Co-Chairs, Glaucoma 360

8:06 – 8:32 am OPENING KEYNOTE ADDRESS — Drs. Henry and Frederick Sutro Memorial Lecture Interventional Glaucoma: The Why, The Who, and The How Speaker Iqbal Ike K. Ahmed, MD, FRCSC Medical Director, Prism Eye Institute; Associate Professor of Ophthalmology, University of Toronto; Clinical Professor of Ophthalmology, University of Utah

MORNING CATALYST Joel S. Schuman, MD, FACS Professor and Chairman of Ophthalmology, NYU Langone Medical Center, NYU School of Medicine; Professor of Electrical and Computer Engineering, NYU Tandon School of Engineering

8:34 – 9:09 am NEW HORIZONS IN VIRTUAL REALITY Moderators Andrew D. Huberman, PhD Associate Professor of Neurobiology and Ophthalmology, Stanford University; Member, Catalyst for a Cure Biomarker Initiative Felipe Medeiros, MD, PhD Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine Presenting • nGoggle, Inc., Felipe Medeiros, MD, PhD, Professor of Ophthalmology, Vice Chair, Technology, Duke University School of Medicine Companies • Vivid Vision, Ben Backus, PhD, Chief Science Officer

9:09 – 9:14 am INDUSTRY SPOTLIGHT — Santen Inc. Speaker Ram Palanki, PharmD Senior Vice President of Commercial, Americas

9:14 – 10:21 am NEW HORIZONS IN GLAUCOMA DEVICES Moderators E. Randy Craven, MD Chief, Wilmer Eye Institute – Bethesda; Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine Eydie G. Miller-Ellis, MD Professor of Clinical Ophthalmology, Scheie Eye Institute, University of Pennsylvania Presenting • Alcon, a Novartis Division, Richard A. Lewis, MD, Co-Founder, Sacramento Eye Consultants Companies • Allergan, Inc., Michael Robinson, MD, Vice President and Therapeutic Area Head, Anterior Segment and Consumer Eye Care • Camras Vision, Ray Krauss, Chief Executive Officer • Ivantis, Inc., Brett A. Trauthen, Chief Scientific Officer • LumiThera, Clark Tedford, PhD, President and Chief Executive Officer • MicroOptx, Chris Pulling, Chief Executive Officer • Santen Inc., Leonard Pinchuk, PhD, DSc (h.c.), NAE, Founder and Chief Scientific Officer, InnFocus, Inc., a Santen company • Sight Sciences, Inc., Steven Vold, MD, Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor, Glaucoma Today

10:21 – 10:51 am BREAK, EXHIBITS AND NETWORKING OPPORTUNITY

10:51 – 11:26 am INDUSTRY PANEL DISCUSSION: GLAUCOMA DEVICES Moderators Malik Kahook, MD Slater Family Endowed Chair of Ophthalmology, Vice Chair, Clinical and Translational Research; Chief, Glaucoma Service and Director, Glaucoma Fellowship, Professor of Ophthalmology, University of Colorado Steven Vold, MD Founder and Chief Executive Officer, Vold Vision; Chief Medical Editor, Glaucoma Today

Panelists • Allergan, Inc., Jag Dosanjh, Senior Vice President, Eye Care • Glaukos Corporation, Chris M. Calcaterra, Chief Operating Officer • Heidelberg Engineering, Kfir Azoulay, MBA, Head of Strategy • Johnson & Johnson Vision, Jane Rady, Vice President, Business Development, Surgical • New World Medical, Rafael Chan, Chief Commercial Officer • Santen Inc., Ram Palanki, PharmD, Senior Vice President of Commercial, Americas • Carl Zeiss Meditec, Inc., Angelo Rago, Global Head, Ophthalmic Diagnostics

10:11:26 – 11:31 am INDUSTRY SPOTLIGHT — Allergan, Inc. Speaker Jag Dosanjh Senior Vice President, Eye Care

11:31 – 12:09 pm FUNDING INNOVATIONS: VENTURE CAPITAL PANEL DISCUSSION Moderators Emmett Cunningham, Jr., MD, PhD, MPH Partner, Clarus Ventures Andrew Gitkin Managing Director and Head of West Coast Biotechnology Banking, Piper Jaffray Panelists • Juliet Bakker, Managing Director and Founder, Longitude Capital • William J. Link, PhD, Founder, Flying L Partners, Managing Director, Versant Ventures • Heather Preston, MD, Partner and Managing Director, TPG Biotech • Christy Shaffer, PhD, Partner, Hatteras Venture Partners

10:12:09 – 12:14 pm INDUSTRY SPOTLIGHT — Aerie Pharmaceuticals, Inc. Speaker Thomas A. Mitro President and Chief Operating Officer

12:14 – 1:10 pm NETWORKING BUFFET LUNCHEON

AFTERNOON CATALYST George A. Cioffi, MD Edward S. Harkness Professor and Chairman, Columbia University College of Physicians and Surgeons; Ophthalmologist-in-Chief, New York-Presbyterian Hospital/Columbia University Medical Center

1:12 – 2:30 pm NEW HORIZONS IN GLAUCOMA DRUG DELIVERY Moderators James D. Brandt, MD Director of Glaucoma Service, Professor of Ophthalmology and Visual Science, UC Davis Anne L. Coleman, MD, PhD Vice Chair of Department of Ophthalmology, Stein Eye Institute, Frances and Ray Stark Foundation Professor of Ophthalmology, Stein Eye Institute of the David Geffen School of Medicine, University of California, Los Angeles, Professor of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles Presenting • Eyenovia, Inc., Shan Lin, MD, Professor of Clinical Ophthalmology, Director, Glaucoma Service, and Director Glaucoma Companies Fellowship Program, Department of Ophthalmology, UCSF • Glaukos Corporation, Jeff Wells, PharmD, Senior Vice President, Clinical, Regulatory and Quality • Graybug Vision, Inc., Jeffrey L. Cleland, PhD, President and Chief Executive Officer • Mati Therapeutics, Christopher A. Muller, Chief Commercial Officer • Ocular Therapeutix, Michael H. Goldstein, MD, MBA, Chief Medical Officer • Otero Therapeutics, Morgan V. Fedorchak, PhD, President and Chief Technology Officer; Assistant Professor of Ophthalmology, Bioengineering and Clinical & Translational Sciences, University of Pittsburgh • Retroject, Inc., Molly Walsh, MD, Founder and Chief Executive Officer • UCSF, Tejal Desai, PhD, Professor and Chair, Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF • USC, Mark S. Humayun, MD, PhD, Cornelius J. Pings Chair in Biomedical Sciences, Professor of Ophthalmology, Biomedical Engineering and Integrative Anatomical Sciences, Director of the Institute for Biomedical Therapeutics and Co-Director of the USC Roski Eye Institute


PROGRAM (continued) LEADERSHIP

ANDREW G. IWACH, MD Executive Director, Glaucoma Center of San Francisco and Executive Director, Glaucoma Research and Education GroupCo-Founder and Co-Chair, Glaucoma 360Chair, Board of Directors, Glaucoma Research Foundation

Since 2000 Dr. Iwach has served on the Board of Directors for the Glaucoma Research Foundation. He is a Co-Founder of the Eye Surgery Center of San Francisco and is an Associate Clinical Professor of Ophthalmology at UCSF and is on the clinical faculty at California Pacific Medical Center. Dr. Iwach’s clinical research focuses on mitomycin-C use in

ADRIENNE L. GRAVES, PHD Independent Director, Akorn, Inc., Nicox S.A., SurfacePharmaceuticals, and TearLab CorporationCo-Founder and Co-Chair, Glaucoma 360Board of Directors, Glaucoma Research Foundation

Adrienne L. Graves, PhD is a visual scientist by training and a global industry leader in

ophthalmology. From 2002 to 2010 Dr. Graves was President and Chief Executive Officer of the US arm of Santen Inc., Japan’s largest ophthalmic pharmaceutical company. Dr. Graves held various Research and Development roles with Alcon Laboratories including Director of International Ophthalmology. In 2015, the Glaucoma Research Foundation gave her the Catalyst Award for her dedication and leadership in advancing ophthalmic innovation. Dr. Graves received her PhD from the University of Michigan and did a postdoctoral fellowship in visual neuroscience at the University of Paris.

L. JAY KATZ, MD Director, Glaucoma Service,Wills Eye HospitalProfessor of Ophthalmology,Jefferson Medical College Steering Committee, Glaucoma 360Glaucoma Research Foundation

In 2017 Dr. Katz was appointed the Chief Medical Officer of Glaukos Corporation. He is

on the advisory boards of Bausch + Lomb, Allergan, Aerie, and Merck. Dr. Katz is a former member of the board and past treasurer of the American Glaucoma Society and a diplomate and associate examiner for the American Board of Ophthalmology. His interests in glaucoma include drug evaluation, laser and medical management, optic nerve scanning methodologies, and glaucoma surgical techniques. After attending Yale University School of Medicine, he completed his ophthalmology residency at Yale and received glaucoma training at Wills Eye Hospital.

THOMAS M. BRUNNER President and Chief Executive Officer, Steering Committee, Glaucoma 360Glaucoma Research Foundation

Mr. Brunner joined the Glaucoma Research Foundation after a 30-year career in the ophthalmic laser business. He helped introduce major advances including laser photocoagulation

for diabetic retinopathy and laser treatment for secondary cataracts and glaucoma. He served 25 years on the Board of Directors for the American Society for Laser Medicine and Surgery who granted him a “Lifetime Achievement” award. As an advisor or board member for startup companies, he supports new product development to treat glaucoma and other eye diseases. Tom graduated from Lehigh University with a degree in electrical engineering and a MBA from the University of Delaware.

RUTH D. WILLIAMS, MD President,Wheaton Eye ClinicVice Chair, Board of Directors, Steering Committee, Glaucoma 360 Glaucoma Research Foundation

Dr. Williams is the President of the Wheaton Eye Clinic, a 74-year-old ophthalmology practice providing eye care to more than 140,000

patients annually. She is a past president of the American Academy of Ophthalmology and represented ophthalmology at the AMA for a decade and chaired its specialty section. Dr. Williams received a Senior Achievement Award from the Academy and was chosen by her peers for the prestigious “Top Doctors” Award in Chicago. After attending Rush Medical College, she completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

filtering surgery, application of optical coherence tomography in glaucoma, selective laser trabeculoplasty, and numerous drug trials. He currently serves as a scientific reviewer for many top professional publications. Recently he received the Academy’s Life Achievement Award and the Academy’s Secretariat Award.

2:30 – 2:35 pm INDUSTRY SPOTLIGHT — Novartis Alcon Pharmaceuticals Speaker Melissa Liew, MD Vice President and US Medical Head of Ophthalmology

2:35 – 3:20 pm NEW HORIZONS IN PHARMACEUTICALS Moderators Lama Al-Aswad, MD, MPH Associate Professor of Ophthalmology and Glaucoma Fellowship Director, Columbia University Medical Center Robert D. Fechtner, MD Professor and Chair of Ophthalmology, Upstate Medical University, SUNY; Director, Glaucoma Division at Rutgers New Jersey Medical School Presenting • Aerie Pharmaceuticals, Inc., Thomas A. Mitro, President and Chief Operating Officer Companies • Allysta Pharmaceuticals, Henry Hsu, MD, Chief Executive Officer • Bausch + Lomb, Robert Kissling, MD, Vice President, Medical Affairs • Glauconix Therapeutics, Karen Y. Torrejon, PhD, Founder and Chief Science Officer • Novartis Alcon Pharmaceuticals, Melissa Liew, MD, Vice President and US Medical Head of Ophthalmology

3:20 – 3:50 pm BREAK, EXHIBITS AND NETWORKING OPPORTUNITY

3:50 – 4:25 pm INDUSTRY PANEL DISCUSSION: PHARMACEUTICALS Moderators Alan Crandall, MD Presidential Professor of Ophthalmology and Visual Sciences, Senior Vice Chair, Director of Glaucoma and Cataract; Co-Director, Division of International Ophthalmology, John A. Moran Eye Center, Global Outreach Division, University of Utah James C. Tsai, MD, MBA, FACS Chair of Ophthalmology, Mount Sinai Health System, President, New York Eye and Ear Infirmary Panelists • Bausch + Lomb, Tracy M. Valorie, MBA, Senior Vice President and General Manager, US Pharmaceutical and Surgical • Novartis Alcon Pharmaceuticals, Melissa Liew, MD, Vice President and US Medical Head of Ophthalmology • Omar Consulting, Cheryl Rowe-Rendleman, PhD, Managing Consultant • Santen Inc., Ram Palanki, PharmD, Senior Vice President of Commercial, Americas

4:25 – 4:30 pm INDUSTRY SPOTLIGHT — Bausch + Lomb Speaker Tracy M. Valorie, MBA Senior Vice President and General Manager, US Pharmaceutical and Surgical

4:30 – 5:08 pm FDA: GETTING TO NEW HORIZONS Moderators Reay H. Brown, MD Atlanta Ophthalmology Associates Cynthia Mattox, MD, FACS Director of the Glaucoma and Cataract Service, New England Eye Center, Associate Professor and Vice-Chair, Department of Ophthalmology, Tufts University School of Medicine Panelists • Wiley A. Chambers, MD, Deputy Director, Division of Transplant & Ophthalmology Products, Center for Drug Evaluation & Research, FDA • Eugene de Juan, Jr., MD, Founder and Vice-Chairman, ForSight Labs • Malvina Eydelman, MD, Director, Division of Ophthalmic and Ear, Nose and Throat Devices, FDA • Kuldev Singh, MD, MPH, Professor of Ophthalmology, Director, Glaucoma Service, Stanford University School of Medicine

5:08 – 5:21 pm FORUM SUMMATION Speaker Richard A. Lewis, MD Co-Founder, Sacramento Eye Consultants

5:21 – 5:30 pm CLOSING REMARKS Adrienne L. Graves, PhD and Andrew G. Iwach, MD

5:30 – 7:00 pm RECEPTION, EXHIBITS, AND NETWORKING OPPORTUNITY


ADVISORY BOARD

STUART B. ABELSON, MBA

President, Chief Executive OfficerOra, Inc.

ANTHONY P. ADAMIS, MD

Vice President, Global Head of OphthalmologyGenentech, Inc.

JAMES D. BRANDT, MD

Director of Glaucoma ServiceProfessor of Ophthalmology and Vision ScienceUniversity of California, Davis

ERNEST CAVIN, PHD

PresidentHaag-Streit USA

PAUL CHANEY

President and Chief Executive OfficerPanOptica, Inc.

GEORGE A. CIOFFI, MD

Jean and Richard Deems Professor of Ophthalmology Edward S. Harkness Professor and ChairmanColumbia University College of Physicians and Surgeons

ALAN S. CRANDALL, MD

Presidential Professor of Ophthalmology and Visual ServicesSenior Vice Chair, Director of Glaucoma and CataractCo-Director, Division of International OphthalmologyJohn A. Moran Eye Center

EMMETT CUNNINGHAM, JR., MD, PHD, MPH

Managing PartnerClarus Ventures

EUGENE DE JUAN, JR., MD

Founder and Vice-ChairmanForSight Labs

JOHN G. FLANAGAN, PHD, FCOPTOM

Dean, School of Optometry and Professor of Optometry and Vision ScienceUniversity of California, Berkeley

DAVID GUYER, MD PartnerSV Life Sciences Advisers, LLC

EVE HIGGINBOTHAM, SM, MD

Vice Dean, Inclusion and Diversity Perelman School of MedicineUniversity of Pennsylvania

H. DUNBAR HOSKINS, JR., MD

Co-Founder and Emeritus Director Glaucoma Research FoundationFormer Executive Vice PresidentAmerican Academy of Ophthalmology

WENDE HUTTON

General PartnerCanaan Partners

ELIOT LAZAR, MD

PresidentelCON Medical

PAUL P. LEE, MD, JD

F. Bruce Fralick Professor and Chair, Department of Ophthalmology and Visual SciencesDirector, W.K. Kellogg Eye CenterUniversity of Michigan

RICHARD L. LINDSTROM, MD

FounderMinnesota Eye Consultants, PA

WILLIAM J. LINK, PHD

Founder Flying L Partners Managing Director

Versant Ventures

CYNTHIA MATTOX, MD, FACS

Director of the Glaucoma and Cataract Service, New England Eye CenterAssociate Professor and Vice-Chair, Department of OphthalmologyTufts University School of Medicine

JAMES MAZZO

Global President Ophthalmic DevicesCarl Zeiss Meditec, Inc.

J. CASEY MCGLYNN, JD

PartnerWilson Sonsini Goodrich & Rosati

GARY D. NOVACK, PHD

PresidentPharmaLogic Development, Inc.

DAVID E.I. PYOTT, CBE

Former Chairman of the Board, President and Chief Executive Officer (1998-2015)Allergan, Inc.

THOMAS W. SAMUELSON, MD

Founding Partner, Minnesota Eye ConsultantsAdjunct Associate Professor of Ophthalmology, University of Minnesota

KULDEV SINGH, MD, MPH

Professor of OphthalmologyDirector, Glaucoma ServiceStanford University School of Medicine

GEORGE SPAETH, MD

Louis Esposito Research Professor of OphthalmologyDirector Emeritus, Glaucoma ServiceWills Eye Hospital/Jefferson Medical College

ELLEN STRAHLMAN, MD, MHSC

Chief Medical Officer and Senior Vice President, Research & DevelopmentBecton, Dickinson and Company

TRACY M. VALORIE, MBA

Senior Vice President and General Manager, US Pharmaceutical and Surgical Bausch + Lomb

ROBERT N. WEINREB, MD

Chairman & Director, Shiley Eye CenterDirector, Hamilton Glaucoma CenterUniversity of California, San Diego

RUTH D. WILLIAMS, MD

PresidentWheaton Eye Clinic

M. ROY WILSON, MD, MS

PresidentWayne State University


IQBAL IKE F. AHMED, MD, FRCSC

Medical Director, Prism Eye InstituteAssociate Professor of Ophthalmology, University of Toronto Clinical Professor of Ophthalmology, University of Utah

LAMA A. AL-ASWAD, MD

Associate Professor of Ophthalmology Columbia University Medical Center

ANNE L. COLEMAN, MD, PHD Vice Chair of Department of Ophthalmology, Stein Eye Institute, Frances and Ray Stark Foundation Professor of Ophthalmology, Stein Eye Institute of the David Geffen School of Medicine, University of California, Los Angeles, Professor of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles

ROBERT D. FECHTNER, MD

Empire Innovation Scholar and ChairDepartment of OphthalmologyUpstate Medical UniversityExecutive Vice President, World Glaucoma Association

LARRY HAIMOVITCH

FounderHaimovitch Medical Technology Consultants

L. JAY KATZ, MD

Director, Glaucoma Service

Wills Eye Institute Professor of Ophthalmology Thomas Jefferson University

RICHARD A. LEWIS, MD

Co-Founder Sacramento Eye Consultants Past President, American Glaucoma SocietyPast President, American Society of Cataract and Refractive Surgery

SHAN LIN, MD

Professor of Clinical OphthalmologyDirector, Glaucoma Service, and Director, Glaucoma Fellowship ProgramDepartment of OphthalmologyUniversity of California, San Francisco

EYDIE G. MILLER-ELLIS, MD

Professor of Clinical OphthalmologyDirector, Glaucoma Service, Scheie Eye InstituteUniversity of Pennsylvania

MILDRED M.G. OLIVIER, MD

Professor and Assistant Dean for Diversity and Learning Environment Rosalind Franklin University of Medicine and Science Chicago Medical School Associate Clinical Professor, Midwestern UniversityCEO and Founder, Midwest Glaucoma Center, P.C.

JOEL S. SCHUMAN, MD, FACS

Professor and Chairman of OphthalmologyNYU Langone Medical Center, New York University School of MedicineProfessor of Electrical and Computer EngineeringNYU Tandon School of Engineering

ROBERT STAMPER, MD

Distinguished Professor of Clinical OphthalmologyDirector Emeritus, Glaucoma ServiceUniversity of California, San Francisco

JAMES C. TSAI, MD, MBA, FACS

Chair of Ophthalmology, Mount Sinai Health SystemPresident, New York Eye & Ear Infirmary

DEVESH K. VARMA, BENG, MD, FRSC

Assistant Professor, Faculty of MedicineUniversity of Toronto

STEVEN VOLD, MD

Founder and CEO Vold VisionChief Medical Editor Glaucoma Today

BARBARA WIROSTKO, MD

Clinical Adjunct Associate ProfessorUniversity of Utah School of Medicine

PROGRAM COMMITTEE

ONE CYPASS® MICRO-STENT IS ALL IT TAKES TO CONNECTTO SAFE, CONSISTENT, LONG-TERM IOP CONTROL

and done

© 2017 Novartis 09/17 US-CYP-17-E-2272

FOR AN EXPERIENCE LIKE NO OTHER, CONNECT WITH AN ALCON REPRESENTATIVE TODAY.

IN THE COMPASS STUDY AT TWO YEARS1,2:• 72.5% of patients achieved a ≥20% reduction in IOP (n=374)• 93% of patients were medication free*• Safety profi le similar to cataract surgery alone

References: 1. CyPass® Micro-Stent Instructions for Use. 2. Vold S, Ahmed IIK, Craven ER, et al. Two-year COMPASS trial results: supraciliary microstenting with phacoemulsifi cation in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123(10):2103-2112.

FOR THE REDUCTION OF IOP IN MILD TO MODERATE PRIMARYOPEN-ANGLE GLAUCOMA AT THE TIME OF CATARACT SURGERY

*Those patients who attained an unmedicated mean diurnal IOP reduction of 20% or more as compared to baseline in the absence of IOP-a� ecting surgery during the study.

and done

IMPORTANT PRODUCT INFORMATIONCAUTION: FEDERAL (USA) LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A PHYSICIAN. INDICATION: The Micro-Stent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG). CONTRAINDICATIONS: Use of the CyPass Micro-Stent is contraindicated in the following circumstances or conditions: (1) in eyes with angle-closure glaucoma; and (2) in eyes with traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle. MRI INFORMATION: The CyPass Micro-Stent is magnetic resonance (MR) Safe: the implant is constructed of polyimide material, a non-conducting, non-metallic, non-magnetic polymer that poses no known hazards in all magnetic resonance imaging environments. WARNINGS: Gonioscopy should be performed prior to surgery to exclude peripheral anterior synechiae (PAS), rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. PRECAUTIONS: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the CyPass Micro-Stent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, in eyes with signi� cant prior trauma, chronic in� ammation, eyes with an abnormal anterior segment, eyes with chronic in� ammation, eyes with glaucoma associated with vascular disorders, pseudophakic eyes with glaucoma, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other secondary open-angle glaucomas, eyes that have undergone prior incisional glaucoma surgery or cilioablative procedures, eyes with laser trabeculoplasty performed ≤ 3 months prior to the surgical screening visit, eyes with unmedicated IOP less than 21 mmHg or greater than 33 mmHg, eyes with medicated IOP greater than 25 mmHg, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL implantation for visually signi� cant cataract. The safety and effectiveness of use of more than a single CyPass Micro-Stent has not been established. ADVERSE EVENTS: In a randomized, multicenter clinical trial comparing cataract surgery with the CyPass Micro-Stent to cataract surgery alone, the most common postoperative adverse events included: BCVA loss of 10 or more letters at 3 months after surgery (8.8% for the CyPass Micro-Stent vs. 15.3% for cataract surgery only); anterior chamber cell and � are requiring steroid treatment 30 or more days after surgery (8.6% vs. 3.8%); worsening of visual � eld mean deviation by 2.5 or more decibels (6.7% vs. 9.9%); IOP increase of 10 or more mmHg 30 or more days after surgery (4.3% vs. 2.3%); and corneal edema 30 or more days after surgery, or severe in nature (3.5% vs. 1.5%). ATTENTION: PLEASE REFER TO THE INSTRUCTIONS FOR A COMPLETE LIST OF CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, AND ADVERSE EVENTS.

100438 US-CYP-17-E-2272 G360.indd 1 1/4/18 12:59 PM

BEN BACKUS, PHD

Vivid Vision Chief Science Officer

Ben Backus was a professor at SUNY Optometry in New York until his recent move to be CSO at Vivid Vision in San Francisco. Dr. Backus is now applying his knowledge of psychophysics to develop a new mobile light-weight perimeter

for people with glaucoma to do visual field testing at home. He trained in mathematics (BA Swarthmore), human vision (PhD UC Berkeley), and visual neuroscience (postdoc Stanford). The NIH, NSF, and HFSP fund his research.

KFIR AZOULAY, MBA

Corporate Head of Strategy Heidelberg Engineering, Inc.

At Heidelberg Engineering, Mr. Azoulay oversees business development as well as the company’s other strategic initiatives. Prior to Heidelberg Engineering Mr. Azoulay served for several years as VP & General Manager of Lumenis’

global ophthalmology business. Mr. Azoulay currently also serves on the Board of Directors of Gauss Infomed (China) and Medisoft Ltd. (UK) — two leading companies in ophthalmic healthcare IT solutions. Mr. Azoulay holds an MBA from the Massachusetts Institute of Technology (MIT) and he also completed the ophthalmology science program (BCSC) at Columbia University.

SPEAKERS, MODERATORS, PARTICIPANTS

LAMA AL-ASWAD, MD, MPH

Associate Professor of Ophthalmology Columbia University Medical Center

Dr. Al-Aswad is an Associate Professor of Ophthalmology at CUMC and the glaucoma fellowship director. She received her MD from Damascus University, and completed a research fellowship at the MEEI, Harvard Medical School.

She completed her residency at SUNY Downstate and Fellowship at UT Memphis. She received her MPH from Columbia University, Mailman School of Public Health with an emphasis on healthcare policy and management. She has been the director of the glaucoma screening program since 2006 and in 2016 she launched Tele-ophthalmology for the four leading causes of blindness.

Opening Keynote Address DRS. HENRY AND FREDERICK SUTRO MEMORIAL LECTURER

IQBAL IKE F. AHMED, MD, FRCSC

Medical Director, Prism Eye Institute Associate Professor of Ophthalmology, University of Toronto Clinical Professor of Ophthalmology, University of Utah

INTERVENTIONAL GLAUCOMA: THE WHY, THE WHO, AND THE HOW Dr. Ahmed’s areas of subspecialty expertise include: surgical management of glaucoma, the complex cataract, and management of cataract and intraocular lens complications. He is actively involved in research and medical education at a national and international level and has received many research grants and has designed diamond scalpels for glaucoma surgery, microsurgical instrumentation, and devices, implants, and techniques for the management of the dislocated cataract and glaucoma. He has published numerous peer-reviewed articles and book chapters and has won many awards and honors for papers, posters, and videos and has given more than 500 scientific presentations and lectures around the world.


JULIET BAKKER

Managing Director and Founder Longitude Capital

Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste

Management International. Previously, she was a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. Ms. Bakker holds an M.P.A. from the John F. Kennedy School of Government at Harvard University and a BSc from the College of Agriculture and Life Sciences at Cornell University (“CALS”).



RAFAEL CHAN

Chief Commercial Officer New World Medical

Mr. Chan recently joined New World Medical as Chief Commercial Officer. Prior to joining New World Medical, Mr. Chan spent over 16 years with Alcon in a variety of commercial strategy and leadership positions across Surgical and

Pharmaceutical franchises, most recently as Head of Marketing for US Surgical. Mr. Chan holds a Bachelor’s Degree and MBA from Vanderbilt University.

CHRIS M. CALCATERRA

Chief Commercial Officer Glaukos Corporation

Mr. Calcaterra has served as Chief Commercial Officer since April 2008. Prior to joining Glaukos, he was Senior VP at Advanced Medical Optics, Inc. and was responsible for its cataract business. Prior to that, Mr. Calcaterra held VP positions

in sales and marketing roles at Advanced Medical Optics, Inc., as well as its predecessor surgical division at Allergan, Inc. He recently served as a board member of WaveTec Vision Systems, Inc. and has a BS from Miami University and an MBA from Xavier University.

WILEY A. CHAMBERS, MD

Deputy Director, Division of Transplant and Ophthalmology Products Center for Drug Evaluation and Research FDA

In addition to his position at the FDA, Dr. Chambers is a Clinical Professor of Ophthalmology and Adjunct Assistant Professor

of Computer Medicine at The George Washington University. He joined the FDA in 1987 and in 1990 became a Supervisory Medical Officer for Ophthalmologic Drug Products. He has supervisory responsibility for the clinical review of ophthalmologic drug products and ophthalmic therapeutic biologic products submitted to the FDA for study and potential approval. Dr. Chambers received numerous Public Health Service, FDA and Center for Drug Evaluation and Research awards for his work.

INSERTION NOTES:

BAU7014_GLAUCOMA_360_AD_8.5X11_M01.INDD

NOTES:

IMAGES:

FONTS:

background_blue_CMYK_8.75X11.25.psd (CMYK; 300 ppi; 100%), VYZULTA_Logo_KO.eps (1333%, 96.45%), B+L_logo_CMYK.ai (17.65%), VYZULTA_BottleAndBox_CMYK_Final.psd (CMYK; 539 ppi; 55.62%)

Interstate (Bold, Regular, Light)

INKS:

ECD

GCD

CSM

AD

CW

ACCT

PM

PROD. ART.

PROOF

PROD. MGR.

NONE

NONE

NONE

NONE

NONE

NONE

NONE

MARK NICHOLSON

NONE

NONE

VERSION

UNIT

BLEED

TRIM

LIVE

VIEWING

GUTTER

SCALE

DPI

ACTUAL

NONE

NONE

8.75” x 11.25”

8.5” x 11”

7.5” X 10”

8.5” x 11”

None

1” : 1”

NONE

8.5” X 11”

1-4-2018 2:48 PM

None

PUB: NONE

CLOSE DATE: NONE

INSERTION DATE: NONE

CLIENT APPROVAL:

DOCUMENT PRINTED AT: NONE

Cyan, Magenta, Yellow, Black

IMAGES:background_blue_CMYK_8.75X11.25.psd (CMYK; 300 ppi; 100%), VYZULTA_Logo_KO.eps (1333%, 96.45%), B+L_logo_CMYK.ai (17.65%), VYZULTA_BottleAndBox_CMYK_Final.psd (CMYK; 539 ppi; 55.62%)

INTRODUCING VYZULTANow available in pharmacies nationwide.

VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affi liates.©2017 Bausch & Lomb Incorporated. All rights reserved. VYZ.0360.USA.17

For more information, visit vyzultanow.com

S:7.5”

S:10”

T:8.5”

T:11”

B:8.75”

B:11.25”

JAMES D. BRANDT, MD

Professor of Ophthalmology and Vision Science Director of Glaucoma ServiceUniversity of California, Davis

Dr. Brandt received his BS from Yale University and an MD from Harvard Medical School, then pursued a two-year post-doctoral research fellowship at the Schepens Eye Research

Institute before his residency at the Doheny Eye Institute. His research interests are in the material properties of the eye as they affect the measurement of intraocular pressure and the physiology of outflow resistance. He is currently collaborating with researchers in the fields of nanotechnology, micro-fabrication and biomedical engineering to develop new methods to measure outflow resistance in the living human eye.

REAY H. BROWN, MD

Glaucoma Editor of EyeWorld Atlanta Ophthalmology Associates

Dr. Brown did his training at Harvard College, University of Michigan Medical School, the Wilmer Eye Institute at Johns Hopkins and the Bascom Palmer Eye Institute. He was the Pamela Firman professor at Emory University before

founding Atlanta Ophthalmology Associates. Their patents on trabecular bypass are fundamental to MIGS technology and cover aspects of many innovative devices including the iStent (Glaukos) and the Hydrus (Ivantis). Dr. Brown has received the Innovator Award from the American Glaucoma Society and the 2017 Charles Kelman Innovator Award from the American Society of Cataract and Refractive Surgery.

GEORGE A. CIOFFI, MD

Edward S. Harkness Professor and Chairman Columbia University College of Physicians and SurgeonsOphthalmologist-in-Chief New York Presbyterian Hospital/Columbia University Medical Center

Dr. Cioffi is the Edward S. Harkness Professor and Chairman at Columbia University, Department

of Ophthalmology. He also holds the Jean and Richard Deems Endowed Professorship and is the Ophthalmologist-in-Chief at New York Presbyterian Hospital. In 2014, he was elected as President of the Columbia Doctors Faculty Practice Organization and was appointed Vice Dean for Clinical Affairs. Dr. Cioffi has received support from the National Eye Institute and has received many awards throughout his career. He continues to mentor clinical and post-doctoral fellows that are now at academic institutions and in practices around world.


JEFFREY L. CLELAND, PHD

President and Chief Executive Officer Graybug Vision, Inc.

Dr. Cleland has 25 years of industry experience in research and development. He has played major roles in obtaining more than $450 million in capital including over $300 million in capital raised as CEO of Versartis (VSAR), where he led

one of the top biotech IPOs of all time. He has directly managed all aspects of pharmaceutical development and late-stage research. Dr. Cleland has authored more than 100 articles and 4 books, and holds several issued patents. He holds a PhD in Chemical Engineering from the Massachusetts Institute of Technology.


ANNE L. COLEMAN, MD, PHD

Vice Chair of Department of Ophthalmology Stein Eye Institute Frances and Ray Stark Foundation Professor of Ophthalmology Stein Eye Institute of the David Geffen School of Medicine, University of California, Los Angeles Professor of Epidemiology

Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles

Dr. Coleman’s research includes the etiology, diagnosis, treatment, and societal impact of glaucoma, cataracts, and age-related macular degeneration, including quality-of-life research for patients impacted by these eye diseases. Dr. Coleman studied chemistry at Duke University, received her MD degree with Alpha Omega Alpha honors from the Medical College of Virginia, completed an ophthalmology residency at University of Illinois-Chicago followed by a glaucoma fellowship at Johns Hopkins University, and earned a PhD in epidemiology from UCLA in 1997.

ALAN S. CRANDALL, MD

Presidential Professor of Ophthalmology and Visual Services; Senior Vice Chair, Director of Glaucoma and Cataract; Co-Director, Division of International Ophthalmology John A. Moran Eye Center Global Outreach Division, University of Utah

Dr. Crandall is a member of the American Academy of Ophthalmology, American Society

of Cataract and Refractive Surgery, American Glaucoma Society, the European Society of Cataract and Refractive Surgeons, as well as the International Intra-Ocular Implant Club. He received his medical degree from the University of Utah School of Medicine. Dr. Crandall completed his internship in surgery at the University of Pennsylvania Medical Center as well as his residency and fellowship in ophthalmology at the Scheie Eye Institute, University of Pennsylvania. He joined the University of Utah Ophthalmology Department in 1981.

E. RANDY CRAVEN, MD, FACS

Associate Professor Wilmer Eye Institute and Johns Hopkins UniversityMedical Director Wilmer Eye Institute – Bethesda

Dr. Craven is an associate professor at the Wilmer Eye Institute. He is an associate professor

at Johns Hopkins University. In the 1990s until 2013, he was the president of Glaucoma Consultants of Colorado in the Denver area and participated in well over 100 clinical trials. He served as the chief of Glaucoma at the King Khaled Eye Specialist Hospital in Riyadh Saudi Arabia from 2013 to 2017. His current role is the Medical Director of the Bethesda location for Wilmer Eye Institute.

EMMETT CUNNINGHAM, JR., MD, PHD, MPH

Managing Partner Clarus Ventures

Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease. He joined Clarus Ventures in 2006. He is Director of the Uveitis Service at California

Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford University, and a Research Associate at The Francis I. Proctor Foundation, UCSF School of Medicine. Dr. Cunningham received his MD and MPH from Johns Hopkins University, his PhD from UC San Diego, and completed his residency and fellowship at UCSF. He completed additional fellowships at Moorfields Eye Hospital in London and the Wilmer Eye Institute.

EUGENE DE JUAN, JR., MD

Founder and Vice-Chairman ForSight Labs

Dr. de Juan serves as Vice-Chairman of ForSight Labs and is the Jean Kelly Stock Distinguished Professor in Ophthalmology at UCSF. He has participated in the development of a number of new technologies and venture-funded

companies. He has previously served as Professor of Ophthalmology at USC and CEO at the Doheny Retina Institute, Co-Director of Vitreoretinal Service at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, Director of the Microsurgery Advanced Design Laboratory, and Joseph E. Green Professor of Ophthalmology. He completed his MD and internship training at the University of South Alabama College of Medicine.

Corneal Endothelium—There is an increased potential for developing corneal edema in patients with low endothelial cell counts.Severe Hepatic or Renal Impairment (CrCl <30 mL/min)—SIMBRINZA® Suspension has not been specifi cally studied in these patients and is not recommended.Acute Angle-Closure Glaucoma—The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. SIMBRINZA® Suspension has not been studied in patients with acute angle-closure glaucoma.Contact Lens Wear—The preservative in SIMBRINZA® Suspension, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of SIMBRINZA® Suspension but may be reinserted 15 minutes after instillation.Severe Cardiovascular Disease—Brimonidine tartrate, a component of SIMBRINZA® Suspension, had a less than 5% mean decrease in blood pressure 2 hours after dosing in clinical studies; caution should be exercised in treating patients with severe cardiovascular disease.Potentiation of Vascular Insu� ciency—Brimonidine tartrate, a component of SIMBRINZA® Suspension, may potentiate syndromes associated with vascular insu� ciency. It should be used with caution in patients with depression, cerebral or coronary insu� ciency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans.Contamination of Topical Ophthalmic Products After Use—There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers have been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

INDICATIONS AND USAGESIMBRINZA® (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fi xed combination indicated in the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and AdministrationThe recommended dose is one drop of SIMBRINZA® Suspension in the a� ected eye(s) three times daily. Shake well before use. SIMBRINZA® Suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least fi ve (5) minutes apart.

IMPORTANT SAFETY INFORMATION

ContraindicationsSIMBRINZA® Suspension is contraindicated in patients who are hypersensitive to any component of this product and neonates and infants under the age of 2 years.

Warnings and PrecautionsSulfonamide Hypersensitivity Reactions—Brinzolamide is a sulfonamide, and although administered topically, it is absorbed systemically. Sulfonamide attributable adverse reactions may occur. Fatalities have occurred due to severe reactions to sulfonamides. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

TURN TO THE STRENGTH OF SIMBRINZA®�1,2NEED TO TURN DOWN IOP?

Treatment Arm 8 AM 10 AM 3 PM 5 PM

PGA + SIMBRINZA® Suspension (n=83)

PGA + Vehicle (n=92)

Baseline 24.5 22.9 21.7 21.6

Baseline 24.3 22.6 21.3 21.2

Week 6† 21.5 20.3 20.0 20.1

Week 6† 19.4 15.8 17.2 15.6

7.1mm Hgreduction

†Di� erences (mm Hg) at week 6 time points between treatment groups were -2.1 (P=0.0002), -4.6 (P<0.0001), -2.8 (P<0.0001), and -4.4 (P<0.0001).2

Primary End Point2

• Mean diurnal IOP (IOP averaged over all daily time points) at week 6 between treatment groups

Key Secondary End Points2

• Mean IOP for each daily time point at week 6

• Mean diurnal change from baseline to week 6

5.7 mm Hg ADDITIONAL MEAN DIURNAL IOP REDUCTION FROM BASELINE2*

Events occurring in approximately 3 to 9% of the subjects, in descending order, included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision, and muscular pain.

Drug InteractionsConsider the following when prescribing SIMBRINZA® Suspension:Concomitant administration with oral carbonic anhydrase inhibitors is not recommended due to the potential additive e� ect. Use with high-dose salicylate may result in acid-base and electrolyte alterations. Use with CNS depressants may result in an additive or potentiating e� ect. Use with antihypertensives/cardiac glycosides may result in additive or potentiating e� ect on lowering blood pressure. Use with tricyclic antidepressants may blunt the hypotensive e� ect of systemic clonidine and it is unknown if use with this class of drugs interferes with IOP lowering. Use with monoamine oxidase inhibitors may result in increased hypotension.For additional information on SIMBRINZA® Suspension, please refer to the Brief Summary of Prescribing Information on the following page.References: 1. SIMBRINZA® Suspension [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; 2015. 2. Fechtner RD, Myers JS, Hubatsch DA, Budenz DL, DuBiner HB. Ocular hypotensive e� ect of fi xed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye (Lond). 2016;30(10):1343-1350.

SAFETY INFORMATION (continued)Adverse ReactionsSIMBRINZA® SuspensionIn two clinical trials of 3 months’ duration with SIMBRINZA® Suspension, the most frequent reactions associated with its use occurring in approximately 3 to 5% of patients in descending order of incidence included: blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, and eye allergy. Adverse reaction rates with SIMBRINZA® Suspension were comparable to those of the individual components. Treatment discontinuation, mainly due to adverse reactions, was reported in 11% of SIMBRINZA® Suspension patients.

Brinzolamide 1%In clinical studies of brinzolamide ophthalmic suspension 1%, the most frequently reported adverse events reported in 5 to 10% of patients were blurred vision and bitter, sour, or unusual taste. Adverse events occurring in 1 to 5% of patients were blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.

Brimonidine Tartrate 0.2%In clinical studies of brimonidine tartrate 0.2%, adverse events occurring in approximately 10 to 30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus.

FOR PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION1

SIMBRINZA® SUSPENSION HAS THE STRENGTH TO TURN DOWN IOP WHEN ADDED TO A PGA2

SIMBRINZA® Suspension should be taken at least fi ve (5) minutes apart from other topical ophthalmic treatments.1

UP TO 7.1 mm Hg ADDITIONAL IOP REDUCTION FROM BASELINE2*

* Study Design: A prospective, randomized, multicenter, double-blind, parallel-group study of 182 patients with open-angle glaucoma and/or ocular hypertension receiving treatment with a PGA. PGA treatment consisted of travoprost, latanoprost, or bimatoprost. Patients in the study were randomized to adjunctive treatment with SIMBRINZA® Suspension (n=88) or vehicle (n=94). The primary eª cacy end point was the di� erence in mean diurnal IOP (IOP averaged over all daily time points) at week 6 between treatment groups. Key secondary end points included IOP at week 6 for each daily time point (8 AM, 10 AM, 3 PM, and 5 PM) and the di� erence in mean diurnal IOP change from baseline to week 6 between treatment groups.2

Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936-1080 © 2017 Novartis 9/17 SMZ-1349618

See more e� cacy and information at www.TurnDownIOP.com


MORGAN V. FEDORCHAK, PHD

President and Chief Technology Officer Otero Therapeutics, Assistant Professor of Ophthalmology, Bioengineering, and Clinical and Translational Science University of Pittsburgh

Dr. Fedorchak is the Director of the Ophthalmic Biomaterials Laboratory at the University

of Pittsburgh and a co-inventor of the SoliDrop technology, the basis for Otero’s controlled release glaucoma eye drop technology. She received her BS in Chemical Engineering from Carnegie Mellon University and her PhD in Bioengineering from the University of Pittsburgh.

TEJAL DESAI, PHD

Ernest L. Prien Endowed Professor and Chair, Dept. of Bioengineering and Therapeutic Sciences, School of Pharmacy and Medicine University of California, San Francisco

Dr. Desai is the founding director of the UCSF/UC Berkeley Masters Program in Translational Medicine. She is Chair-Elect of the American

Institute for Medical and Biological Engineering College of Fellows. Dr. Desai’s research includes materials engineering, cell biology, tissue engineering, and pharmacological delivery systems to address issues concerning disease and clinical translation. She received her BS from Brown University in biomedical engineering and was awarded a PhD in bioengineering jointly from UCSF and UC Berkeley. In 2015, she was elected to the National Academy of Medicine.


MALVINA EYDELMAN, MD

Division Director, Division of Ophthalmic Device Evaluation FDA

Dr. Eydelman is a board-certified ophthalmologist. She received her undergraduate degree in Electrical Engineering from Cooper Union for the Advancement of Science and Art. She received

her MD degree from Harvard Medical School and a PhD in Health Sciences and Technology from Massachusetts Institute of Technology. In 1995, Dr. Eydelman joined the FDA and has played a key role in assuring the safety and effectiveness of ophthalmic medical devices. She has been involved in standardization of ophthalmic devices as the US Expert Delegate to the International Standards Organization and FDA’s Liaison to the American National Standards Institute’s Committee for Ophthalmic Devices.

ROBERT D. FECHTNER, MD

Professor Institute of Ophthalmology and Visual Science Director Glaucoma Division, Rutgers New Jersey Medical School

Dr. Fechtner chairs the Institutional Review Board for human subject research at the New Jersey

Medical School in Newark. He is also the Executive Vice President of the World Glaucoma Association. Dr. Fechtner is a highly regarded glaucoma educator. He has organized major glaucoma symposia for the American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, the World Glaucoma Congress and the American Glaucoma Society. He has served on the editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, Review of Ophthalmology, and Video Journal of Ophthalmology.

ANDREW GITKIN

Managing Director and Head of West Coast Biotechnology Investment Banking Piper Jaffray

Andrew has over 25 years of healthcare investment experience, most recently at Moelis & Company, where he was a Senior VP in the life sciences investment banking group. Andrew

was previously with Saddle Point Asset Management where he was a managing member and healthcare portfolio manager. Prior to that, he was a VP at Tavistock Life Sciences and was CEO of Zephyr Sciences. Andrew was also a senior healthcare analyst in equity research at UBS and SalomonSmithBarney where he was awarded rankings by Institutional Investor and Greenwich Associates.

JAG DOSANJH

Senior Vice President, Eye CareAllergan, Inc.

Jag is responsible for the commercialization of the entire Eye Care portfolio in the US and co-chairs the R&D Governance Board for the pipeline development. Prior to this, he led the Retina, Dermatology, and SkinMedica business

units, and the Managed Markets and Government Affairs. Jag also led the Global Strategic Marketing developing strategy and delivery of the pipeline within the pharmaceutical, device and aesthetics portfolios. Prior to joining Allergan, Jag worked at GlaxoSmithKline in several executive roles in both Europe and the US. He holds a BA in Business Studies from Sheffield in the UK.


SHAN LIN, MD

Professor, Clinical Ophthalmology, Director, Glaucoma Service UCSF and the Zuckerberg San Francisco General Hospital

Dr. Lin’s interests include: angle closure glaucoma; glaucoma among Asians; cyclodestructive procedures; and the role of cataract surgery in

glaucoma treatment. His past honors include the Heed Fellowship Award, the American Glaucoma Society and The Glaucoma Foundation’s Clinician-Scientist Awards, and the Mid-Career Award by the AGS. As a Principal Investigator, his OHTS study was funded by the NIH, in addition to him receiving many industry-funded trials including the Memantine Glaucoma Trial by Allergan and the Ranibizumab-Adjunctive Study for Ahmed Valve Surgery by Genentech. He has received the AAO’s Achievement Award, Secretariat Award, and Senior Achievement Award.

WILLIAM J. LINK, PHD

Founder, Flying L PartnersManaging Director, Versant Ventures

In 1987 Bill founded and served as chairman and CEO of Chiron Vision (sold to Bausch + Lomb). He founded and served as President of American Medical Optics, which was sold to Allergan. Bill served on the Board of AMO’s

successor company, Advanced Medical Optic, later acquired by Abbott and later acquired by Johnson & Johnson. Bill serves on the Board of several private companies and three public companies: Glaukos, Second Sight and Edwards Lifesciences. Previously, Bill was Assistant Professor, at Indiana University School of Medicine. He received his BS, MS and PhD in Mechanical Engineering from Purdue University.

MELISSA LIEW, MD

Vice President and US Medical Unit Head, Ophthalmology Novartis Alcon Pharmaceuticals

Dr. Liew is responsible for medical affairs strategy across the ophthalmology portfolio. Previously, Melissa was VP and Therapeutic Area Head for Retina at Novartis, leading

retina clinical development strategy and global development programs. Prior to Novartis, she worked at Pfizer Ophthalmics on translational to late stage development including retina, glaucoma and dry eye projects. As a Wellcome Trust researcher, her genetic epidemiology of retinal diseases and macular pigment research earned her a European Society of Ophthalmology award. Melissa received her MD from University College, London and completed her Ophthalmology residency at Moorfields and a glaucoma fellowship at Wills Eye. She is a board certified Ophthalmologist.


MARK S. HUMAYUN, MD, PHD

Cornelius J. Pings Chair in Biomedical Sciences, Professor of Ophthalmology, Biomedical Engineering, and Integrative Anatomical Sciences, Director USC Institute for Biomedical Therapeutics Co-Director USC Roski Eye Institute

Dr. Humayun has dedicated 30 years to the development of the first FDA-approved bioelectronic artificial retina to restore sight to the blind and enable them to see large objects and letters. He has more than 200 peer-reviewed publications and 114 issued patents and is the recipient of the 2015 National Medal of Technology and Innovation — the nation’s highest award for technological achievement.

RAY KRAUSS, MBA

Chief Executive Officer Camras Vision

Ray has 35 years executive experience in the medical device industry, including 10 years at Johnson & Johnson (venture capital/ophthalmology). He joined Summit Technology as COO, the first company to

receive FDA clearance for PRK in 1995. He has been CEO of several startups, raised financing from Angel Investors and VC firms, and has led the sale of two companies to strategic partners. Ray holds BS and MS degrees in Electrical Engineering and an MBA.

ROBERT KISSLING, MD

Vice President, Medical Affairs Bausch + Lomb

Robert Kissling, MD has more than 15 years of experience in the eye care industry and pharmaceutical industry including Pharmacia, Novartis, QLT, Galderma, and Bausch + Lomb.

HENRY HSU, MD

Chief Executive Officer Allysta Pharmaceuticals

Dr. Hsu has extensive experience in all phases of drug development in multiple indications, including glaucoma, dry eye, and retinal diseases. Prior to founding Allysta, Henry was CEO of Altheos. He has led clinical development teams

at Molecular Partners, CoMentis, and Plexxikon. Allysta is partnered with D. Western Therapeutics Institute (Japan) to advance a novel multi-kinase inhibitor (H1337) for glaucoma into clinical trials in early 2018 in the United States. Dr. Hsu obtained his MD from UCSF.

18 Glaucoma Research Foundation

ANDREW D. HUBERMAN, PHD

Assistant Professor, Neurobiology and Ophthalmology Stanford University School of Medicine

Dr. Huberman received his PhD in Neuroscience from UC Davis. From 2005-2010 he was a Helen Hay Whitney Postdoctoral Fellow at Stanford University. From 2011 to 2015, he

was an Assistant Professor in the Departments of Neuroscience, Biology and Ophthalmology at UC San Diego. In 2016, joined the faculty at Stanford University. Dr. Huberman is a McKnight Foundation Neuroscience Scholar, a Biomedical Scholar of the Pew Charitable Trust and in 2017, he received the ARVO Cogan Award for Contributions to Vision Science and Ophthalmology. Dr. Huberman is member of the Glaucoma Research Foundation Catalyst for a Cure Biomarker Initiative.

MALIK Y. KAHOOK, MD

Slater Family Endowed Chair of Ophthalmology, Vice Chair of Clinical and Translational Research, Chief, Glaucoma Service and Director of Glaucoma Fellowship, Professor of Ophthalmology University of Colorado Aschutz Medical Campus

Dr. Kahook is Professor of Ophthalmology and The Slater Family Endowed Chair in Ophthalmology at the University of Colorado School of Medicine. He is Vice Chair of Clinical and Translational Research and is Chief of the glaucoma service and Director of the glaucoma fellowship at the University of Colorado Eye Center. Dr. Kahook has also received numerous awards and filed for over 30 patents with 20 licensed by companies for development. Four of his devices are currently in human trials or available globally for clinical use.

RICHARD A. LEWIS, MD

Co-founder Sacramento Eye Consultants

In addition to his clinical practice, Dr. Lewis is involved in clinical research trials in anterior segment disease and glaucoma therapy. He previously served as President of both the American Society of Cataract and Refractive

Surgery and the American Glaucoma Society. Dr. Lewis is the medical Editor Emeritus of Glaucoma Today and on the editorial board of the Journal of Cataract and Refractive Surgery, Journal of Glaucoma, and Ocular Surgery News. Dr. Lewis attended UC Berkeley and received his MD from Northwestern University Medical School. His completed his residency at the UC Davis, and a fellowship at the University of Iowa.

CYNTHIA MATTOX, MD, FACS

Associate Professor and Vice-Chair, Department of Ophthalmology at Tufts University School of Medicine; Director of the Glaucoma and Cataract Service at the New England Eye Center

Dr. Mattox has served on the American Glaucoma Society (AGS) Board since 2008 and

was elected President in 2017. She has served on the Health Policy committee of the American Academy of Ophthalmology (AAO) for many years. In 2014, she received the Outstanding Advocate Award from the AAO, and in 2016 was elected to a four-year term on the AAO Board of Directors. Along with her busy practice, Dr. Mattox trains glaucoma fellows and residents in glaucoma and cataract management and surgery, and has received the Resident Teaching Award three times.

MICHAEL H. GOLDSTEIN, MD, MBA

Chief Medical Officer Ocular Therapeutix

Dr. Goldstein joined Ocular Therapeutix in 2017. Prior to that, Dr. Goldstein served as CMO of Applied Genetic Technologies Corp, a clinical-stage biotechnology company focused on the treatment of rare ophthalmic diseases. Before

joining AGTC, Dr. Goldstein served as CMO and VP of Clinical Research at Eleven Biotherapeutics. Dr. Goldstein serves as Co-Director, Cornea and External Disease Service and Assistant Professor of Ophthalmology at the New England Eye Center and Tufts University School of Medicine. Dr. Goldstein holds an MD and an MBA from Northwestern University.



CHRISTOPHER A. MULLER

Chief Commercial Officer Mati Therapeutics, Inc.

Prior to Mati Therapeutics, Mr. Muller served as the Chief Commercial Officer at QLT Inc. Before that, he was responsible for several business units at Abbott Medical Optics as VP, Eye Care, Medical Marketing and the Refractive Business Unit with

responsibility for VISX® and iFS laser platforms, contact lens solutions, artificial tear development and commercialization, plus ophthalmic surgical products. For 15 years Mr. Muller was employed at Allergan Inc. where he built an extensive background across all ocular pharmaceutical and surgical products and Botox®, including sales, health economics, worldwide medical marketing, and product management.

EYDIE MILLER-ELLIS, MD

Professor of Clinical Ophthalmology Director, Glaucoma Services Scheie Eye Institute

While maintaining a busy glaucoma practice, Dr. Miller-Ellis lectures nationally and internationally on glaucoma diagnosis and management. She is a three-time recipient of

the Surgical Teaching Award at the Scheie Eye Institute, Co-Vice Chair of the American Academy of Ophthalmology’s (AAO) Ophthalmic Knowledge Base panel for glaucoma, chair of the AAO’s COMPASS panel for glaucoma, and a 2008 recipient of the AAO Achievement Award. She received her MD from the University of Pittsburgh and did her ophthalmology residency at UNC, Chapel Hill, and a glaucoma fellowship at Yale.

THOMAS A. MITRO

President and Chief Operating Officer Aerie Pharmaceuticals

Prior to serving as President and COO of Aerie Pharmaceuticals, Tom served as VP, Sales and Marketing at Omeros Corp and ISTA Pharmaceuticals. He held various positions at Allergan, Inc., including VP, Skin Care; VP,

Business Development; and VP, e-Business. Tom has been an invited guest speaker to the Ophthalmic Innovation Summit, Generic Drug industry, the Dermatology Leadership Council and OCTANe. He currently serves on the Board of Directors at OCTANe. Tom received his BS degree from Miami University.

RAM PALANKI, PHARMD

Senior Vice President of Commercial, Americas Santen Inc.

Dr. Palanki brings over 15 years of ophthalmology experience across marketing, sales, reimbursement, commercial operations, business development, and medical affairs.

Previously, he was Global Head of Marketing and Sales at Thrombogenics, Inc., where he led the commercial launch for Jetrea®, a therapy for symptomatic VMA. Prior to that, Dr. Palanki served as Director of Global Marketing and Sales at NeoVista, Inc., and earlier, he held several positions at Genentech as part of the team that developed and launched Lucentis®. Other past positions include Eyetech Pharmaceuticals and Novartis Pharmaceuticals. Dr. Palanki earned his PharmD at Albany College of Pharmacy and completed his postdoctoral fellowship at Rutgers University in New Jersey.

LEONARD PINCHUK, PHD

Chief Science Officer Inn Focus, Inc., a Santen company

Dr. Pinchuk co-founded Innovia LLC, which incubated and spun off into eight companies. In 2016 Santen Corporation acquired his current company, InnFocus, Inc. His major accomplishments include the invention or

co-invention of the modern-day angioplasty balloon and other cardiovascular stents, several biomaterials, a novel glaucoma shunt, and next generation intraocular lens material. He received a BSc in Chemistry and an honorary Doctor of Science degree from McGill University and a PhD interdisciplinary in Engineering and Chemistry from the University of Miami where he is a Research Professor of Biomedical Engineering. He was inducted into AIMBE and the National Academy of Engineering.

FELIPE MEDEIROS, MD, PHD

Professor of OphthalmologyVice Chair of Technology Duke University School of Medicine

Dr. Medeiros completed his MD and residency at the University of Sao Paulo School of Medicine, followed by a fellowship at the Hamilton Glaucoma Center at UC San Diego and PhD

in Vision Science from the University of Sao Paulo. His research focuses on the development of innovative methods to diagnose and detect glaucoma. Dr. Medeiros evaluates the impact of eye diseases on daily activities, using innovative techniques such as virtual reality. His laboratory was the first to use virtual reality to predict a clinically relevant functional outcome in medicine.

www.ellex.com/SLT-ABIC-natural-partnership

Naturally.Working together.

PREVIEW THE BREAKTHROUGH Tango Reflex™ SLT/LFR/YAG LASER AT GLAUCOMA 360

SLT and ABiC™ work to control IOP by a process of restoration of the natural outflow pathways. This is in contrast to traditional glaucoma surgeries and other MIGS procedures, which attempt to mechanically change or bypass the pathway of aqueous outflow.

SLT stimulates a process of cellular regeneration to create a healthier, more porous TM structure. On average, SLT achieves a 30% reduction in IOP when used as a first-line therapy.

ABiC™ is a new ab-interno MIGS procedure that flushes out the natural outflow channels, without damaging tissue, to achieve an average IOP reduction of 30%*.

*E&OE. © 2018 Ellex Medical. * 228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.

LEARN MORE AT WWW.ELLEX.COM/SLT-ABIC-NATURAL-PARTNERSHIP

A restorative approach to IOP control.

ELLEX-ABiC SLT-Glaucoma 360-2018.indd 1 19/12/2017 3:24 pm


APRIL 12, 2018WASHINGTON, DC

999 Ninth Street NW WashingtonDistrict Of Columbia 20001

CELEBRATING 10 YEARS OF INNOVATION

UNITING OVER500 LEADERS IN THE DEVELOPMENT OF GROUND-BREAKING OPHTHALMIC TECHNOLOGIES

WWW.OIS.NET /OIS.NET� @OISTWEETS� /OPHTALMOLOGYSUMMIT�

RENAISSANCE WASHINGTON, DC DOWNTOWN


HEATHER PRESTON, MD

Partner and Managing Director TPG Biotech

Prior to TPG Biotech, Dr. Preston focused on medical device and biotechnology venture capital investing at JP Morgan Partners. Previously, she was an Entrepreneur-in-Residence with New Enterprise Associates. She

worked at McKinsey & Co. where she was a leader of their pharmaceutical and medical products consulting practice. Dr. Preston currently serves on the board of directors of Albireo, Inc., Alder BioPharmaceuticals, Otonomy, Inc., Unchained, Labs, Avalyn Pharmaceuticals, Azura Ophthalmics and Entasis, Inc. She earned her MD from the University of Oxford and completed a molecular biology post-doctoral fellowship at Dana Farber Cancer Institute, Harvard University. She trained in Internal Medicine at Massachusetts General Hospital and subspecialized in Gastroenterology and Hepatology at UCSF.

CHRIS PULLING

Chief Executive Officer MicroOptx

Prior to MicroOptx, Chris was CEO of The Integra Group, a contract research organization he founded in 2002. He led Integra from formation through acquisition by the world’s largest medical device CRO. At Integra, Chris

and his staff supported over 400 medical device companies, and he was integrally involved in over 30 PMA approvals and 10 FDA advisory panels. Previous management experience also includes Medtronic. Chris has an MS in Biostatistics from the University of Minnesota and a BA in Mathematics from Hamline University.

JANE RADY

Vice President, Business Development Johnson & Johnson Vision

Prior to joining Johnson & Johnson Vision and Abbott Medical Optics, Ms. Rady was a director and the CEO of Integrated Genomics, Inc., held senior positions within G.D. Searle & Co., and headed venture investing in Monsanto focusing

on emerging technologies and businesses in biotechnology.Ms. Rady began her career with Abbott Laboratories. She received her Bachelor and Master of Science from the University of Illinois in molecular biology/microbiology and her MBA from Northwestern’s Kellogg School of Management.

ANGELO RAGO

Head of Ophthalmic Diagnostics Carl Zeiss Meditec, Inc.

Currently Mr. Rago is focused on Retina and Glaucoma and the Routine Diagnostics businesses. He joined ZEISS as Head of Business Sectors and Innovation within the Strategic Business Unit Ophthalmic Systems. Previously,

Mr. Rago held various management positions in Equipment Operations and Global Customer Care for Abbott Medical Optics (AMO). Prior to AMO, he spent 17 years with Siemens Medical Solutions, where he held senior positions in both Service and Product Development areas. He holds a BS in Mechanical Engineering and an Executive Certification in Innovation & Strategy from MIT’s Sloan School of Business.

MICHAEL R. ROBINSON, MD

Vice-President, Therapeutic Area Head, Anterior Segment and Consumer Eye Care Allergan, Inc.

Dr. Robinson is a board-certified ophthalmologist who completed 3 years of post-doctoral fellowship training at the National Eye Institute with a focus on ocular drug delivery. Given his

broad clinical and research background, Dr. Robinson has served in multiple leadership roles at Allergan including Global Project Team Lead and Clinical Lead on projects related to ocular drug delivery in dry eye, retina and glaucoma therapeutic areas. He has over 20 issued patents that include Bimatoprost SR and Brimonidine DDS, both in late stages of clinical development.

CHERYL ROWE-RENDLEMAN, PHD

Managing Consultant Omar Consulting Group, LLC

Dr. Rowe-Rendleman is a clinical research and development professional at Omar Consulting Group, an ophthalmology consulting practice specializing in creating business, regulatory, and clinical development know-how for people

and companies interested in eye diseases. A graduate of Princeton University with graduate fellowships in developmental and degenerative ophthalmic diseases from the University of Texas and UCSF Medical Schools, Cheryl has participated in over 100 US and Ex-US clinical development programs in areas of macular degeneration, diabetic retinopathy, ocular inflammation, anti-infectives, refractive disorders, glaucoma, and ocular surface disease.


PRACTICAL REVIEWS from LEADING EXPERTSPEER-REVIEWED | OPEN-ACCESS | CONCISEARTICLES | VIDEOS | NEWS

touchOPHTHALMOLOGY.com

VIEW – DOWNLOAD – SUBSCRIBE

FREE

Touch Medical Media is the trading name of Touch Digital Media Ltd

touchOPHTH A5 WGA2017 proof3.indd 1 04/01/2018 10:08


JOEL S. SCHUMAN, MD, FACS

Professor and Chairman of Ophthalmology NYU Langone Medical Center, New York University School of MedicineProfessor of Electrical and Computer Engineering NYU Tandon School of Engineering

Dr. Schuman was appointed Chair of the Department of Ophthalmology for the NYU

Langone Medical Center in 2016. Dr. Schuman and his colleagues invented optical coherence tomography (OCT), now standard of care for clinical use worldwide for the diagnosis and management of eye disease. His team was also the first to identify a molecular marker for human glaucoma, published in Nature Medicine in 2001. Dr. Schuman is a productive researcher, and has been continuously funded by the National Eye Institute since 1995. He serves on the Glaucoma Research Foundation’s Catalyst for a Cure Biomarker Initiative’s Advisory Board.

CHRISTIE SHAFFER, PHD

Partner Hatteras Ventures

Christy Shaffer, PhD has over 25 years of experience in the life science industry. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at

Burroughs Wellcome Co., she joined Inspire Pharmaceuticals. Dr. Shaffer serves as a board member of five Hatteras portfolio companies and chairs three of them: Clearside (Chair), KinoDyn (Chair), and GrayBug (Executive Chair). She is a receptor pharmacologist by training, earning her PhD in Pharmacology from the University of Tennessee Health Science Center. She received her post-doctoral training at The Chicago Medical School and the University of North Carolina at Chapel Hill.

KULDEV SINGH, MD, MPH

Professor of OphthalmologyDirector of Glaucoma Service Stanford University School of Medicine

Singh has served as President of the American Glaucoma Society and Executive Vice President of the World Glaucoma Association. He is presently a Standing Member on the Medical

Devices Advisory Committee of the US Food and Drug Administration. Dr. Singh received his MD and MPH degrees from the Johns Hopkins University School of Medicine and was an Eleanor Naylor Dana Charitable Trust Fellow at the Wilmer Eye Institute. He completed his ophthalmology residency at Casey Eye Institute and his glaucoma fellowship at at the Bascom Palmer Eye Institute.

CLARK E. TEDFORD, PHD

Co-Founder, President and Chief Executive Officer LumiThera

Dr. Tedford is one of the founders of LumiThera and has served as President and CEO since the formation of the company. Previously he was VP and Chief Science Officer at PhotoThera. Prior to

that Dr. Tedford was the VP, Pharmaceutical Research at Omeros, and previously to Omeros, Dr. Tedford was President of Solentix, Inc. During Dr. Tedford’s 25 years in the pharmaceutical and medical device industry, he has held several scientific and executive management positions. Dr. Tedford received his PhD in pharmacology from the University of Iowa and completed post-doctoral work at the Loyola University Medical School.

KAREN Y. TORREJON, PHD

Founder, Chief Science Officer Glauconix Therapeutics

During graduate research supported by the National Science Foundation Graduate Research Fellowship Program (NSF GRFP), Dr. Torrejon invented 3D human eye tissue, known as the 3D-human trabecular meshwork (3D-HTM).

She developed this proprietary technology which is currently being utilized for Glauconix services. Dr. Torrejon has been recognized by the MIT technology review and one of the “35 under 35” innovators of the year (2015). She received her BS in both Chemistry and Physics from the State University of New York (SUNY) at Albany and her PhD in Nanoscale Engineering from SUNY Polytechnic Institute.

BRETT A. TRAUTHEN

Chief Scientific Officer Ivantis, Inc.

Mr. Trauthen is the Chief Scientific Officer for Ivantis, Inc, developer of the Hydrus Microstent, a novel surgical device for IOP reduction in glaucoma. Prior to Ivantis, he was the Chief Scientific Officer at Devax Inc and

Conor Medsystems, developers of drug eluting coronary stents. Mr. Trauthen has directed over 20 clinical studies on novel technologies in ophthalmic and cardiovascular disease. He has a BS in Engineering from UC Berkeley and an MS is Engineering from UC Irvine.

ACKNOWLEDGEMENTS


Board ChairAndrew G. Iwach, MDUniversity of CaliforniaSan Francisco, CA President and CEO Thomas M. BrunnerGlaucoma Research FoundationSan Francisco, CA

TreasurerCharles WilmothWells Fargo Advisors, LLC.San Francisco, CA

Vice ChairRuth D. Williams, MDWheaton Eye ClinicWheaton, IL

SecretaryRick Halprin, CPAAlcon Laboratories, Inc. (Retired)Fort Worth, TX

DIRECTORS

Frederick H. Brinkmann(Retired)Palo Alto, CA

Timothy J. DwyerPrivate InvestorWoodside, CA

John G. Flanagan, PhD, FCOptomUniversity of California, BerkeleyBerkeley, CA

Adrienne L. Graves, PhDIndependent DirectorSan Francisco, CA

Linda C. LinckDelta Gamma FoundationLafayette, CA

Dennis E. SingletonSpieker PartnersMenlo Park, CA

Robert L. Stamper, MDUniversity of CaliforniaSan Francisco, CA

Monica L. Vetter, PhDUniversity of UtahSalt Lake City, UT

Martin B. Wax, MDPanOptica, Inc.Bernardsville, NJ

Mona ZanderMona and Ed Zander Family FoundationCarmel, CA

BOARD OF DIRECTORS

FOUNDERS

John Hetherington, Jr., MDUniversity of CaliforniaSan Francisco, CA

H. Dunbar Hoskins, Jr., MDAmerican Academy of Ophthalmology (Retired)San Francisco, CA

Robert N. Shaffer, MD, FACS(1912 – 2007)

Sincere Thanks to our Media and Strategic Partners

4-R Vision

Bryn Mawr Communications

Healthegy

Jacqueline Jones Design

Market Scope

Ophthalmology Innovation Summit

Ophthalmology Times

Rotary Club of San Francisco

touchOphthalmology

MEDIA AND STRATEGIC PARTNERS


JAMES C. TSAI, MD, MBA

President of New York Eye and Ear Infirmary of Mount Sinai Chair of Ophthalmology, Mount Sinai Health SystemDelafield-Rodgers Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai

Dr. Tsai serves as Chair of the Glaucoma Subcommittee of the National Eye Health

Education Program Planning Committee of the National Institutes of Health (NIH), Associate Examiner for the American Board of Ophthalmology, and Treasurer of the International Joint Commission on Allied Health Personnel in Ophthalmology. Dr. Tsai earned his MD from Stanford University School of Medicine and his MBA from Vanderbilt University. He completed his residency at the Doheny Eye Institute and received his glaucoma fellowship training at the Bascom Palmer Eye Institute and at Moorfields Eye Hospital and the Institute of Ophthalmology in London.

STEVEN D. VOLD, MD

Founder and Chief Executive Officer Vold VisionChief Medical Editor Glaucoma Today

Dr. Vold founded Vold Vision after previously serving as Vice Chairman of the Department of Ophthalmology and Director, Division of

Glaucoma at the Scott and White Eye Institute and Texas A&M College of Medicine in Temple, Texas. He has been listed in the Consumer’s Research Council of America’s Guide to America’s Top Ophthalmologists every year since 2002. He currently serves as Chief Medical Editor of Glaucoma Today, and co-founded the American-European Congress of Ophthalmic Surgery. Dr. Vold also co-founded the ophthalmic device company Ocunetics, Inc. whose intellectual property was exclusively licensed by IRIDEX Corporation in 2011.

TRACY M. VALORIE, MBA

Senior Vice President and General Manager US Pharmaceutical and SurgicalBausch + Lomb

Ms. Valorie is the Senior Vice President and General Manager of Bausch + Lomb Pharmaceuticals and Valeant Women’s Health and previously served as the Global Head of Glaucoma.

Prior to that, Ms. Valorie was Pfizer’s Commercial Lead of Ophthalmology where she was responsible for marketed products, mid-stage development portfolio, and long-range planning. Her 20+ year career has included roles in discovery science, clinical development, early commercial assessment, marketing, and strategic planning. Ms. Valorie has held board membership seats at The Glaucoma Foundation, ARVO foundation for Eye Research, and OWL.

MOLLY WALSH, MD

Co-founder and Chief Executive Officer Retroject, Inc.

Dr. Walsh is the co-founder and CEO of Retroject, Inc, a company that she started with her late colleague, Dr. David Epstein. Dr. Walsh is a glaucoma specialist at Duke University Eye Center where numerous patients are treated

daily for unnecessary vision loss due to the inadequacies of topical therapies. Her research interests are focused on a device that enables delivery of therapeutic agents directly to the sites responsible for causing elevated intraocular pressure in glaucoma, the trabecular meshwork and Schlemm’s canal.

JEFF WELLS, PHARMD

Senior Vice President of Clinical, Regulatory, and Quality Glaukos Corporation

Prior to working at Glaukos, Jeff was Senior VP of Product Development at Bioform, and held various roles at Santen Inc. including VP US R&D, VP Clinical and Regulatory Affairs for the US and

Europe, and Director of Marketing. Prior to Santen, he worked at Bausch + Lomb, where he launched Lotemax and several other products. Jeff holds a BS and BA from Ohio Northern University, a Masters in Management (MBA) from the Kellogg School at Northwestern University, and a PharmD from the University of Florida.

Founded in 1978 in San Francisco, Glaucoma Research Foundation was created to encourage innovative research to find better ways to care for people with glaucoma and ultimately find a cure.

Over the past 40 years, Glaucoma Research Foundation has funded pioneering and transformational studies to advance the field of glaucoma. An important funding priority is fostering collaborative research in order to speed the pace of discovery. Landmark projects include the Collaborative Normal Tension Glaucoma Study, the first controlled clinical trial to establish that lowering eye pressure preserves vision, and the establishment of the Catalyst for a Cure (CFC) research consortium.

Established in 2001, our first CFC team focused on neuroprotection and fundamentally changed how the scientific and medical communities view vision loss in glaucoma. Based on this successful model, the second CFC team was recruited and charged with identifying new biomarkers to indicate the earliest signs of glaucoma. The researchers have moved their investigations from the laboratory into the clinic for human studies of the most promising biomarkers they have identified. The impact of this research will be valuable for both patients and doctors as it has the potential to transform how glaucoma is diagnosed and managed in the future.

COMMITMENT TO EDUCATION AND AWARENESSGlaucoma Research Foundation remains a principal source of information and support for doctors, patients and their families. We distribute more than 120,000 issues of our Gleams newsletter three times a year through the mail, by doctors’ offices and by email. Our website, www.glaucoma.org, helps more than 4 million visitors annually with useful and accurate information. Both our website and our educational booklet “Understanding and Living with Glaucoma” continue to be primary resources for patients seeking to learn more about their glaucoma diagnosis, treatment options, and Glaucoma Research Foundation’s research initiatives.

THE CURE IS IN SIGHT CAMPAIGNIn April 2017, The Cure is in Sight — The Campaign for Glaucoma Research Foundation was launched with the goal to raise $15 million by June 2018. This historic fundraising endeavor will reinforce our mission, strengthen our education and support efforts, and make possible great strides in scientific discovery. In 2018, we will close the Campaign and mark the 40th anniversary of the founding of Glaucoma Research Foundation. As we celebrate these important milestones, we incredibly grateful for the outstanding support and dedication of our donors and volunteers. Because of you, the cure is truly in sight.

Our Proud Legacy…

…and Inspired Future

GLAUCOMA RESEARCH FOUNDATION

GRF founders in 1989 (from left to right): the late Robert Shaffer, MD, H. Dunbar Hoskins, Jr., MD, and John Hetherington, Jr., MD

28 Glaucoma Research Foundation

Friday, February 8, 2019Palace Hotel, San Francisco

New Horizons Forum2019

Please direct early inquiries to [email protected]

SAVE THE DATE!

speeding the development of new therapies and diagnostics ...10:21 – 10:51 am • graybug vision,...

Documents